Drugs

Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA Drug Information Soundcast in Clinical Oncology (DISCO) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Download from ITunes

Latest Drug Information Soundcasts

TitleDateLink to PodcastLink to Transcript

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur
In our inaugural podcast, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks with hosts Dr. Sanjeeve Bala and Dr. Abhilasha Nair about this new podcast series.

May 16, 2017Listen to This Podcast
Run Time:
00:3:19
Transcript

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer who have been treated with two or more chemotherapies.

May 17, 2017Listen to This Podcast
Run Time:
00:5:13
Transcript

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

May 18, 2017

Listen to This Podcast
Run Time:
00:5:56

Transcript

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

May 22, 2017

Listen to This Podcast
Run Time:
00:6:28

Transcript

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval
The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

May 30, 2017

Listen to This Podcast
Run Time:
00:6:00

Transcript
FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
 July 25, 2017Listen to This Podcast
Run Time:
00:9:00
  
Transcript
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. 
 July 28, 2017Listen to This Podcast
Run Time:
00:6:00
  
Transcript 

 

Page Last Updated: 07/28/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English